A Phase III trial evaluating use of adjuvant endocrine therapy in patients with high-risk hormone receptor-positive and HER2/negative Breast Cancer

Cancer - Breast, Cancer
Grace Makari-Judson, MD
D’Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without your cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. The combination of hormone-treatment and everolimus is experimental in patients with breast cancer.
Invasive non-metastatic breast cancer; ER/PR positive; HER2 negative
Rae Lynn Defeo